Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
FDMT 
4D Molecular Therapeutics Inc (FDMT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: FDMT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $33.11
1 Year Target Price $33.11
| 5 | Strong Buy |
| 4 | Buy |
| 2 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 59.72% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 619.34M USD | Price to earnings Ratio - | 1Y Target Price 33.11 |
Price to earnings Ratio - | 1Y Target Price 33.11 | ||
Volume (30-day avg) 12 | Beta 2.95 | 52 Weeks Range 2.23 - 12.34 | Updated Date 12/14/2025 |
52 Weeks Range 2.23 - 12.34 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -65538.89% |
Management Effectiveness
Return on Assets (TTM) -27.64% | Return on Equity (TTM) -45.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 336544213 | Price to Sales(TTM) 5161.2 |
Enterprise Value 336544213 | Price to Sales(TTM) 5161.2 | ||
Enterprise Value to Revenue 2804.54 | Enterprise Value to EBITDA -3.55 | Shares Outstanding 57135075 | Shares Floating 42919868 |
Shares Outstanding 57135075 | Shares Floating 42919868 | ||
Percent Insiders 3.23 | Percent Institutions 71.97 |
About 4D Molecular Therapeutics Inc
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2020-12-11 | Co-Founder, CEO & Director Dr. David H. Kirn M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 227 | |
Full time employees 227 | |||
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in EmeryVille, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.